The Deals Keep Getting Bigger
If there was any doubt that artificial intelligence has become the central bet in pharmaceutical R&D, this week erased it. Eli Lilly signed a research and licensing agreement with Insilico Medicine worth up to $2.75 billion — one of the largest deals yet placing a major drugmaker's capital directly behind AI-generated drug candidates. The ink was barely dry before Insilico announced a separate $888 million multi-year collaboration with French pharma company Servier to discover and develop cancer drugs, a deal that landed just days after Insilico's Hong Kong IPO.
Meanwhile, Pfizer quietly signed a license agreement with Chai Discovery, an AI startup focused on accelerating drug identification. And Novo Nordisk — the Danish giant behind the weight-loss and diabetes drug boom — deepened its OpenAI partnership to reshape both drug discovery and its manufacturing operations.
In a single news cycle, these four deals committed billions toward a technology that, until recently, lived mostly in research papers and startup pitch decks.
A Human Trial Milestone
Beyond the boardroom, a genuinely significant scientific result arrived: an AI-designed vaccine targeting coronaviruses has cleared its first human trial. Researchers developed the candidate specifically to address pandemic preparedness — not just one coronavirus strain but a broader family of related viruses. First-in-human success is an early gate, not a finish line, but it validates that AI-designed biologics can survive the rigor of clinical testing in people. For a field that has seen many AI-originated compounds flame out before reaching patients, that matters.
Recursion Pharmaceuticals also reported momentum across its AI-powered pipeline, with new clinical candidates advancing and a $12.5 million milestone payment from partner Rallybio adding to its war chest.
The Skeptics Aren't Wrong
Not everyone is celebrating. A growing body of expert commentary is pushing back on the narrative that AI has already transformed drug development. The core concern: investment has poured in, announcements have multiplied, but clinical proof points remain thin. The pharmaceutical industry has a long history of technological enthusiasm — combinatorial chemistry, high-throughput screening, genomics — that generated enormous hype before eventually finding its appropriate, bounded role.
AI drug discovery is almost certainly not immune to that pattern. The honest read is that the technology is genuinely accelerating certain steps — target identification, molecule generation, trial site selection — while the hardest parts of drug development, predicting clinical efficacy and safety in humans, remain as difficult as ever. The Eli Lilly and Servier deals are bets on potential, not proof.
Insilico's Longevity Ambition
One story that cuts against the purely transactional framing: Insilico Medicine announced what it is calling the industry's first dedicated longevity board, a governance and advisory structure aimed at the biology of aging. It is an unusual move — most pharma companies treat aging as a risk factor for specific diseases, not a target in its own right. Insilico is positioning itself differently, treating longevity science as a strategic pillar alongside its deal-making.
The Bottom Line
Pharmaceutical AI is no longer a fringe bet or a pilot project. It is the organizing logic of the industry's next decade — with billions committed, a human trial cleared, and the first regulatory questions beginning to sharpen. Whether the technology can deliver drugs that actually work in patients at the scale the investment implies is the question that will define the next few years. Today's news suggests the industry has decided not to wait for that answer before placing its chips.